Background Ustekinumab is a monoclonal antibody that targets interleukin (IL)‐12/23 p40 to
treat psoriasis. The IL‐12 pathway is also important in regulating immunity to Mycobacterium …

Background Ustekinumab, an interleukin (IL)‐12 and IL‐23 blocker, has emerged as a new
therapeutic option for patients with psoriasis. It is generally well tolerated but safety data on …

BACKGROUND: Ustekinumab targets interleukin (IL)-12 and IL-23 in the treatment of
moderate to severe psoriasis. OBJECTIVE: We sought to evaluate the impact of …

BACKGROUND: Ustekinumab targets interleukin (IL)-12 and IL-23 in the treatment of
moderate-to-severe psoriasis. OBJECTIVE: To evaluate overall pooled study data to assess …

Background Long‐term safety evaluations of biologics are needed to inform patient
management decisions. Objectives To evaluate the safety of ustekinumab in patients with …

However, South Korea has a higher tuberculosis burden than other developed countries. 4
We used the National Health Insurance Service database to select patients who were …

Background An unmet need remains for safe and effective long‐term treatments of psoriasis.
Objectives To evaluate ustekinumab efficacy and safety for up to 3 years in the PHOENIX 1 …

Background The efficacy and safety profile of ustekinumab with up to three years of
exposure suggested a favorable benefit-risk profile in patients with moderate to severe …

BACKGROUND: Ustekinumab has been evaluated in Caucasian patients with psoriasis, but
no studies have been conducted in Asian patients. OBJECTIVE: To assess the efficacy and …

Background Ustekinumab, a human monoclonal antibody against interleukins 12 and 23,
has shown therapeutic potential for psoriasis. This study assessed the efficacy and safety of …